Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
BuchKartoniert, Paperback
357 Seiten
Englisch
Springererschienen am15.07.20221st ed. 2021
This book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced clinical development.mehr
Verfügbare Formate
BuchGebunden
EUR171,19
BuchKartoniert, Paperback
EUR171,19

Produkt

KlappentextThis book summarizes state-of-the-art antiviral drug design and discovery approaches starting from natural products to de novo design, and provides a timely update on recently approved antiviral drugs and compounds in advanced clinical development.
Zusammenfassung
Summarizes antiviral drug design and discovery approaches

Provides the latest update in the field of antiviral therapeutics

Includes antiviral research of coronaviruses
Details
ISBN/GTIN978-981-16-0269-6
ProduktartBuch
EinbandartKartoniert, Paperback
Verlag
Erscheinungsjahr2022
Erscheinungsdatum15.07.2022
Auflage1st ed. 2021
Seiten357 Seiten
SpracheEnglisch
IllustrationenXI, 357 p. 142 illus., 64 illus. in color.
Artikel-Nr.50926623
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
1 Antiviral Drugs Against Herpesviruses.- 2 An Update on Antiretroviral Therapy.- 3 Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and their Inhibition.- 4 LEDGINs, Inhibitors of the Interaction between HIV-1 Integrase and LEDGF/p75, are Potent Antivirals with a Potential to Cure HIV Infection.- 5 Moving Fast Towards Hepatitis B Virus Elimination.- 6 Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.- 7 Phytoconstituents as Lead Compounds for Anti-dengue Drug Discovery.- 8 Anti-influenza Drug Discovery and Development: Targeting the Virus and its Host by all.- 9 Search, Identification and Design of Effective Antiviral Drugs against Pandemic Human Coronaviruses.- 10 Peptide Based Antiviral Drugs.- 11 Covalent Antiviral Agents.- 12 Safe-in-Man Broad Spectrum Antiviral Agents.- 13 Exploiting Ubiquitin ligases for Induced Target Degradation as an Antiviral Strategy.mehr

Autor


Luis Menéndez-Arias

Luis Menéndez-Arias received his Ph.D. in biology from the Complutense University of Madrid and was trained as a postdoctoral fellow at the Frederick Cancer Research and Development Center (Frederick, Maryland, USA). Currently, he is a research professor in the Spanish National Research Council and group leader at the Centro de Biología Molecular Severo Ochoa in Madrid.  His research is mainly devoted to understanding structure-activity relationships in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), elucidating mechanisms of HIV resistance to antiretroviral drugs, and understanding HIV replication fitness.  Dr. Menéndez-Arias has co-authored more than 120 peer-reviewed papers and is a member of the editorial boards of Antimicrobial Agents and Chemotherapy, Antiviral Research, Antiviral Therapy, Journal of Biological Chemistry, PLoS One, Virus Research , and Viruses. 

Xinyong Liu

Xinyong Liu received his B.S. and M.S. degrees from the School of Pharmaceutical Sciences, Shandong University. Then, he worked at the Instituto de Quimica Medica (CSIC) in Madrid, Spain, as a senior visiting scholar. Dr. Liu obtained his Ph.D. from Shandong University. He is currently a full professor at the Institute of Medicinal Chemistry, Shandong University. His research interests include rational drug design, synthesis, and antiviral evaluation of a variety of molecules that interact with specific enzymes and receptors in the viral life cycle. Other ongoing programs include studies of the molecular modification and structureâactivity relationships of some natural products used to treat cardiovascular diseases and drug delivery research using PEGylated small-molecular agents.

Peng Zhan

Peng Zhan obtained his B.S. and M.Sc. degrees and a Ph.D. in medicinal chemistry from Shandong University, China. Then, he joined the research group of Professor Xinyong Liu as a lecturer. Later, he worked as a postdoctoral fellow funded by JSPS (Japan Society for the Promotion of Science) in the Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan. Currently, he is a full professor at the Institute of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel antiviral, anticancer, and neurodegenerative diseases-related agents based on rational drug design and combinatorial chemistry approaches.

Vasanthanathan Poongavanam

Vasanthanathan Poongavanam obtained his Ph.D. in medicinal chemistry from the University of Copenhagen, Denmark, working on computational modeling of cytochrome P450-ligand interactions. He conducted his postdoctoral research at the University of Vienna (Austria), University of Southern Denmark (Denmark), and Uppsala University (Sweden). Currently, he is a researcher (Forskare) at Uppsala University (Sweden). His current research activities involve the basic understanding of biomolecular recognition using computer simulations, with emphasis on the prediction of cellular permeability, ligand-binding, molecular properties of compounds in bRo5 space, cheminformatics, and computer-assisted drug design.